ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment

Biochemical Pharmacology

Volumn 77, Issue 1, 2009, Pages 66-75

  Rebecchi, Ivanise Marina Moretti ^a   Rodrigues, Alice Cristina ^a   Arazi, Simone Sorkin ^a   Genvigir, Fabiana Dalla Vecchia ^a   Willrich, Maria Alice Vieira ^a   Hirata, Mario Hiroyuki ^a   Soares, Sarah Aparecida ^a   Bertolami, Marcelo Chiara ^b   Faludi, André Arpad ^b   Bernik, Márcia Martins Silveira ^a   Dorea, Egidio Lima ^a   Dagli, Maria Lucia Zaidan ^a   Avanzo, José Luis ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

ABCB1; ABCC1; Atorvastatin; Gene expression; Pharmacogenetics; Single nucleotide polymorphisms

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTICHOLESTEREMIC AGENTS; FEMALE; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PYRROLES;

EID: 56649105136     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.019     Document Type: Article

References (50)

1. Ho R.H., and Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78 (2005) 260-277
2. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9 (2008) 105-127
3. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
4. Choudhuri S., and Klaassen C.D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25 (2006) 231-259
5. Leschziner G.D., Andrew T., Pirmohamed M., and Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7 (2007) 154-179
6. Hoffmeyer S., Burk O., Von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
7. Kim R.B., Leake B.L., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and Africans Americans. Clin Pharmacol Ther 70 (2001) 189-199
8. Moriya Y., Nakamura T., Horinouchi M., Sakaeda T., Tamura T., Aoyama N., et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25 (2002) 1356-1359
9. Kimchi-Sarfaty C., Oh J.M., Kim I.-W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
10. Sakurai A., Onishi Y., Hirano H., Seigneuret M., Obanayama K., Kim G., et al. Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 46 (2007) 7678-7693
11. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204 (2005) 216-237
12. Fukushima-Uesaka H., Saito Y., Tohkin M., Maekawa K., Hasegawa R., Kawamoto M., et al. Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population. Drug Metab Pharmacokinet 22 (2007) 48-60
13. Conrad S., Kauffmann H.-M., Ito K.-I., Deeley R.G., Cole S.P., and Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671 V substitution. J Hum Genet 46 (2001) 656-663
14. Letourneau I.J., Deeley R.G., and Cole S.P. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15 (2005) 647-657
15. Wang Z., Sew P.H., Ambrose H., Ryan S., Chong S.S., Lee E.J., et al. Nucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region. BMC Genomics 7 (2006) 111
16. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15 (1995) 678-682
17. Vaughan C.J., and Gotto Jr. A.M. Update on statins: 2003. Circulation 110 (2004) 886-892
18. Shitara Y., and Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112 (2006) 71-105
19. Keskitalo J., Kurkinen K., Neuvonen P., and Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84 4 (2008) 457-461
20. Rodrigues A.C., Hirata M.H., and Hirata R.D. The genetic determinants of atorvastatin response. Curr Opin Mol Ther 9 (2007) 545-553
21. Kajinami K., Brosseau M.E., Ordovas J.M., and Schaefer E.J. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93 (2004) 1046-1050
22. Thompson J.F., Man M., Johnson K.J., Wood L.S., Lira M.E., Lloyd D.B., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5 (2005) 352-358
23. Gradhand U., and Kim R.B. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40 (2008) 317-354
24. Genvigir F.D., Soares S.A., Hirata M.H., Willrich M.A., Arazi S.S., Rebecchi I.M., et al. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin Chim Acta 389 (2008) 79-86
25. Chahoud G., Aude Y.W., and Mehta J.L. Dietary recommendations in the prevention and treatment of coronary heart disease: do we have the ideal diet yet?. Am J Cardiol 94 (2004) 1260-1267
26. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
27. Thompson A., and Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259 (2006) 481-492
28. Salazar L.A., Hirata M.H., Cavalli S.A., Machado M.O., and Hirata R.D. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 44 (1998) 1748-1750
29. Rodrigues A.C., Rebecchi I.M., Bertolami M.C., Faludi A.A., Hirata M.H., and Hirata R.D. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 38 (2005) 1389-1397
30. Rodrigues A.C., Curi R., Britto L.R., Rebbechi I.M., Hirata M.H., Bertolami M.C., et al. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta 1760 (2006) 1866-1873
31. Sakaeda T., Nakamura T., and Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25 (2002) 1391-1400
32. Bernal M.L., Sinues B., Fanlo A., and Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit 25 (2003) 107-111
33. Ozawa S., Soyama A., Saeki M., Fukushima-Uesaka H., Itoda M., Koyano S., et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19 CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19 (2004) 83-95
34. Kimchi-Sarfaty C., Marple A.H., Shinar S., Kimchi A.M., Scavo D., Roma M.I., et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8 (2007) 29-39
35. Albermann N., Schmitz-Winnenthal F.H., Z'graggen K., Volk C., Hoffmann M.M., Haefeli W.E., et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 70 (2005) 949-958
36. Janneh O., Jones E., Chandler B., Owen A., and Khoo S.H. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 60 (2007) 987-993
37. Moon Y.J., Zhang S., and Morris M.E. Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes. Acta Haematol 118 (2007) 169-175
38. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276 (2001) 14581-14587
39. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 22 (2003) 7496-7511
40. Synold T.W., Dussault I., and Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7 (2001) 584-590
41. Cornwell M.M., and Smith D.E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268 (1993) 19505-19511
42. Zhu Q., and Center M.S. Evidence that SP1 modulates transcriptional activity of the multidrug resistance-associated protein gene. DNA Cell Biol 15 (1996) 105-111
43. Sundseth R., MacDonald G., Ting J., and King A.C. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 51 (1997) 963-971
44. Yague E., Armesilla A.L., Harrison G., Elliott J., Sardini A., Higgins C.F., et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 278 (2003) 10344-10352
45. Hirai T., Fukui Y., and Motojima K. PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biol Pharm Bull 30 (2007) 2185-2190
46. Sanguino E., Roglans N., Alegret M., Sánchez R.M., Vázquez-Carrera M., and Laguna J.C. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol 145 (2005) 853-861
47. Storch C.H., Klimm H.D., Heinrich T., Haefeli W.E., and Weiss J. Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch Pharmacol 376 (2007) 135-143
48. Valente R.C., Capella L.S., Nascimento C.R., Braga F., Echevarria-Lima J., Lopes A.G., et al. ABCB1 (P-glycoprotein) but not ABCC1 (MRP1) is down regulated in peripheral blood mononuclear cells of spontaneously hypertensive rats. Pflugers Arch 456 (2008) 359-368
49. Markova S., Nakamura T., Sakaeda T., Makimoto H., Uchiyama H., Okamura N., et al. Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metab Pharmacokinet 21 (2006) 194-200
50. Garrigues A., Escargueil A.E., and Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A 99 (2002) 10347-10352